CDK16 as a potential prognostic biomarker correlated with an immunosuppressive tumor microenvironment and benefits in enhancing the effectiveness of immunotherapy in human cancers
Figure 5.Gene alteration of CDK16. (A) The mutation and CNA status of CDK16 in TCGA-pan-cancer. (B) The correlation between CDK16 expression and CNA.